Abstract 233P
Background
Protein polybromo-1 (PB1) encoded by the PBRM1 gene is involved in chromatin-remodeling processes as a part of the SWI/SNF complex. Pathogenic variants of PBRM1 gene are commonly encountered in ccRCC. Much attention has been drawn to the predictive potential of PBRM1 to immunotherapeutic agents’ response in solid tumors. This work aims to establish an interconnection between PBRM1 loss and TIME of ccRCC.
Methods
The ccRCC cohort was obtained from the Cancer Genome Atlas Program (TCGA). Patients were stratified based on the presence of PBRM1 pathological variants into wild type group (n = 213) or mutant group (n = 153). TIME was evaluated through the enrichment of immunological processes-related gene sets using gene set enrichment analysis (GSEA) within the hallmarks of cancer and ontology gene sets. A gene set was considered significantly enriched with a P-value < .05 and a false discovery rate (FDR) ≤ 0.25. Immune cells infiltration was explored using precalculated infiltration scores of xCell. T-cell dysfunction score was obtained from TIDE server.
Results
GSEA illustrated enrichments in three immunological sets within the hallmarks of cancer, including TNF-α signaling through NF-κB (enrichment score (ES) = 0.43, Q value < .001, FDR = 0.007), INF-α response (ES = 0.34, Q value = .03, FDR = 0.190), and INF-γ response (ES = 0.39, Q value < .001, FDR = 0.022). Gene ontology sets screening highlighted the effect of PBRM1 loss on CXCR chemokine receptor binding (ES = 0.75, Q value < .001, FDR = 0.202) with no enriched sets within the cellular component or biological process sections. The mutant group showed a significant CD8+ T-cells depletion alongside reduced infiltration of eosinophils, cancer-associated fibroblasts, M1 macrophages, and T helper 2 cells. PBRM1 damage did not induce a T-cell dysfunction (z score = 0.726, P = .468). In addition, PBRM1 loss was correlated with a superior response to nivolumab in a cohort of 35 patients (fold change = 58.7 and P = .0123).
Conclusions
PBRM1 Loss induces global transcription alternations that impact many immunological processes. Such phenomena could be associated with the positive correlation to immunotherapy response in ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract